Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vagal Stimulation in POTS
NCT03124355Phase 1Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2017
- Primary completion
- Jun 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in postural orthostatic tachycardia syndrome (POTS) comparing Placebo pill with vagal/sham stimulation, Pyridostigmine with vagal/sham stimulation and Galantamine with vagal/sham stimulation (3 arms). Primary endpoint: High frequency variability of heart rate. Started Sep 2017; status: active, not recruiting.
02
Drugs
pyridostigminegalantamine
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT03124355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03124355.